Immuneering (IMRX) Gross Profit (2020 - 2022)
Immuneering's (IMRX) quarterly Gross Profit came in at $455.0 in Q4 2022, up 102.74% year-on-year from $224.43 in Q4 2021, and down 97.61% quarter-over-quarter from $19037.0 in Q3 2022.
Immuneering (IMRX) Gross Profit (2020 - 2022) Analysis & Trends
Immuneering's Gross Profit history runs 3 years deep, the most recent figure standing at $455.0 for Q4 2022.
- On a quarterly basis, Gross Profit rose 102.74% year-over-year to $455.0 in Q4 2022; TTM through Sep 2023 was $455.0, a 99.68% decrease from a year earlier, with the FY2022 full-year figure at $158830.0, down 82.86% from the prior year.
- Gross Profit eased to $455.0 in Q4 2022 per IMRX's latest filing, from $19037.0 in the prior quarter.
- Across five years, Gross Profit topped out at $367568.0 in Q3 2020 and bottomed at -$16630.0 in Q4 2021.
- The 3-year median for Gross Profit is $191847.0 (2020), against an average of $171718.7.
- Across the five-year window, Gross Profit tumbled 108.67% in 2021 and soared 102.74% in 2022, its largest moves.
- Year by year, Gross Profit stood at $191847.0 in 2020, then sank by 108.67% to -$16630.0 in 2021, then surged by 102.74% to $455.0 in 2022.
- Per Business Quant, the three latest IMRX Gross Profit figures stand at $455.0 (Q4 2022), $19037.0 (Q3 2022), and $46486.0 (Q2 2022).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Immuneering | 283.85 Mn | 283.85 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 455.00 |
| Dec 31, 2022 | 455.00 |
| Sep 30, 2022 | 19,037.00 |
| Sep 30, 2022 | 19,037.00 |
| Jun 30, 2022 | 46,486.00 |
| Jun 30, 2022 | 46,486.00 |
| Mar 31, 2022 | 92,852.00 |
| Mar 31, 2022 | 92,852.00 |
| Dec 31, 2021 | -16,630.00 |
| Dec 31, 2021 | -16,630.00 |
| Sep 30, 2021 | 263,042.00 |
| Sep 30, 2021 | 263,042.00 |
| Jun 30, 2021 | 341,439.00 |
| Jun 30, 2021 | 341,439.00 |
| Mar 31, 2021 | 339,037.00 |
| Mar 31, 2021 | 339,037.00 |
| Dec 31, 2020 | 191,847.00 |
| Dec 31, 2020 | 191,847.00 |
| Sep 30, 2020 | 367,568.00 |
| Sep 30, 2020 | 367,568.00 |